B7H3-CART

B7H3-CART is an investigational autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to recognize and attack cells expressing B7-H3 (CD276), a pan-cancer antigen highly and broadly expressed on a variety of pediatric and adult solid tumors, brain tumors, and certain hematologic malignancies. The construct uses a monoclonal antibody-derived binder that provides specificity for the B7-H3 antigen, which is minimally present in normal tissues. B7H3-CART has demonstrated potent antitumor activity in a range of preclinical models, inducing regression in xenograft models of osteosarcoma, medulloblastoma, Ewing sarcoma, and other solid tumor types, and is now being explored in phase 1 clinical trials mainly for relapsed or refractory pediatric and young adult solid tumors. The mechanism involves genetically modifying patient T cells ex vivo to express a CAR that recognizes B7-H3, which, upon infusion, directs T cell cytotoxicity toward B7-H3-expressing tumor cells[1][6][7][9].

Other names

B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TB7-H3-specific CAR TB-7-H3-specific CAR TB 7-H3-specific CAR TB7-H3 chimeric antigen receptor T cellsB-7-H3 chimeric antigen receptor T cellsB 7-H3 chimeric antigen receptor T cells